NCCN Guidelines for Central Nervous System Cancers: Updates in the Treatment of Adult Patients With Glioma

Presented by:
Craig M. Horbinski
Search for other papers by Craig M. Horbinski in
Current site
Google Scholar
PubMed
Close
 MD, PhD
and
L. Burt Nabors
Search for other papers by L. Burt Nabors in
Current site
Google Scholar
PubMed
Close
 MD
Restricted access

In 2021, the WHO revised its classification of central nervous system (CNS) tumors, which has resulted in changes to both the diagnostic and treatment landscapes. At the NCCN 2023 Annual Conference, this tumor board–style presentation featured 4 case studies to demonstrate an evidence-based approach to the treatment of patients with various WHO-defined types of diffuse glioma. The NCCN Guidelines have been updated to reflect the WHO reclassification of CNS tumors and provide treatment recommendations accordingly.

Disclosures: Dr. Horbinski has disclosed no relevant financial relationships. Dr. Nabors has disclosed serving as a scientific advisor for Chimerix.

Correspondence: Craig M. Horbinski, MD, PhD, Robert H. Lurie Comprehensive Cancer Center of Northwestern University, 303 East Superior Street, Chicago, IL 60611. Email: craig.horbinski@northwestern.edu; and

L. Burt Nabors, MD, O’Neal Comprehensive Cancer Center at the University of Alabama, 2000 6th Avenue South, Floor 2, Birmingham, AL 35233. Email: bnabors@uab.edu
  • Collapse
  • Expand
  • 1.

    Nabors LB, Portnow J, Baehring J, et al. NCCN Clinical Practice Guidelines in Oncology: Central Nervous System Cancers. Version 1.2023. Accessed April 6, 2023. To view the most recent version, visit https://www.nccn.org

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 2.

    Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005;352:987996.

  • 3.

    Hegi ME, Diserens AC, Gorlia T, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 2005;352:9971003.

  • 4.

    Buckner JC, Shaw EG, Pugh SL, et al. Radiation plus procarbazine, CCNU, and vincristine in low-grade glioma. N Engl J Med 2016;374:13441355.

  • 5.

    van den Bent MJ, Tesileanu CMS, Wick W, et al. Adjuvant and concurrent temozolomide for 1p/19q non-co-deleted anaplastic glioma (CATNON; EORTC study 26053-22054): second interim analysis of a randomised, open-label, phase 3 study. Lancet 2021;22:813823.

    • PubMed
    • Search Google Scholar
    • Export Citation
All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 2551 2202 158
PDF Downloads 2404 2023 184
EPUB Downloads 0 0 0